We are developing a next-generation technology based on genetically engineered and presorted tumor infiltrating lymphocytes (TILs), which offer a number of important benefits:
- Greater potency and persistence
- Lower cost of goods, shorter manufacturing process
- Cytokine expression enhances modulation of immune-suppressing proteins PD-1 and CTLA-4
- Lower cell numbers required
- Stronger intellectual property protection